Background {#Sec1}
==========

Sleep-disordered breathing (SDB) is a common public health problem with a prevalence of 5--20% in the general population, \[[@CR1], [@CR2]\] although many patients remain undiagnosed. Obstructive sleep apnea is the most common form of SDB, and has been linked to a number of adverse clinical outcomes including increased cardiovascular and all-cause mortality \[[@CR3]\].

The association between SDB and cancer remains to be clearly defined, although previous studies have shown SDB to be associated with increased cancer incidence and cancer mortality. \[[@CR4]--[@CR7]\] Furthermore, it has been shown that sleep time with oxygen saturation below 90% has the strongest association with cancer mortality, highlighting the importance of hypoxemia. \[[@CR4]\] This is supported by animal studies showing that intermittent hypoxia, as occurs in patients with obstructive sleep apnea, was associated with tumor growth and progression. \[[@CR8]\] Underlying mechanisms include angiogenesis, epithelial-mesenchymal transition, migration/invasion, maintenance of cancer stem cells, metastasis, and immune surveillance, as well as resistance to chemotherapy and radiotherapy. As a result, hypoxemia has been linked with poor prognosis in different malignancies \[[@CR9], [@CR10]\].

To the best of our knowledge, there is currently no published data on the prevalence of undiagnosed SDB in patients with newly-diagnosed lung cancer. This is relevant because the presence of SDB might influence morbidity and mortality in lung cancer patients and the treatment of intermittent hypoxia could therefore influence the outcome or response to therapy. This study investigated the prevalence of SDB in patients with newly-diagnosed lung cancer.

Methods {#Sec2}
=======

The study received approval from the Institutional Review Board for Human Studies at the University Hospital RWTH Aachen, Germany (EK 312/13). Written informed consent was provided by each subject before participation. All procedures conformed to the standards set by the Declaration of Helsinki in its latest revision.

Patients {#Sec3}
--------

From 5th August 2014 until 24th February 2017 consecutive patients with newly-diagnosed lung cancer from three different study centres (University Hospital RWTH - Aachen, Florence-Nightingale-Hospital - Düsseldorf, Cologne-Merheim Hospital - Cologne) were included. Inclusion into the study was done before any treatment for lung cancer (surgery, radiotherapy, or chemotherapy) was initiated. Also excluded were patients with a history of any malignancy or previously diagnosed sleep apnea.

Study design {#Sec4}
------------

Patient demographic data, smoking history, and co-morbidities were assessed. Screening for SDB was performed during hospital stay or at home. Daytime sleepiness was assessed using the Epworth Sleepiness Scale (ESS) and Sleep Quality was assessed using the Pittsburgh Sleep Quality Index (PSQI) \[[@CR11], [@CR12]\].

Assessing sleep-disordered breathing {#Sec5}
------------------------------------

SDB screening was performed using a two-channel screening system (ApneaLink Oxi™; ResMed Ltd., Sydney, Australia) which has been validated previously. \[[@CR13], [@CR14]\] The ApneaLink™ measures nasal flow via a cannula and records pulse oximetry; further details are described elsewhere. \[[@CR14]\] Default device settings were used to define apnea, hypopnea and desaturation as follows: apnea was defined as a decrease of at least 80% in airflow for ≥10 s; hypopnea was defined as a decrease in airflow by 50--80% for ≥10 s; desaturation was defined as a ≥ 4% decrease in oxygen saturation. Mild SDB was defined as AHI of 5 to \< 15/h and moderate to severe SDB as an AHI of ≥15/h. \[[@CR15]\] The screening device was read out by one investigator at the University Hospital Aachen who was blinded to the patients' status.

Statistical analysis {#Sec6}
--------------------

Continuous data are presented as mean ± standard deviation and categorical data are tabulated as frequencies and percentages. Groups of patients defined based on cutoff values of AHI were compared using ANOVA, Kruskal-Wallis rank sum test and Chi-square test. Nominal *p*-values are presented for each comparison. Linear models were built using the logarithmic transformed AHI. The following variables were used as independent variables in the models: age (linear effect), sex and body mass index (BMI; linear) were included in all models, and Union for International Cancer Control (UICC) tumor stage (4 categories), arterial hypertension (yes/no), chronic obstructive pulmonary disease (COPD; yes/no) and coronary artery disease (yes/no) were added to the models using all subsets. We present results for the model with the highest adjusted r squared. In additional analyses, AHI was modeled using a generalized linear model with Poisson family and logarithmic link function (data not shown). The prevalence of SDB was estimated from the sample proportions and exact binomial 95% confidence interval (CI) values were calculated.

Results {#Sec7}
=======

Patient characteristics {#Sec8}
-----------------------

During the study period 625 patients were newly diagnosed with lung cancer at the three study centers. Data from 100 patients who fulfilled the inclusion criteria and consented to take part in the study were included. Patient demographic data are shown in Table [1](#Tab1){ref-type="table"}. The most common form of lung cancer was adenocarcinoma, followed by squamous cell carcinoma and small cell lung cancer (Table [1](#Tab1){ref-type="table"}). Sleep and respiratory parameters for the total population are presented in Table [2](#Tab2){ref-type="table"}.Table 1Patient demographic dataPatients (*n* = 100)Age, years68.1 ± 8.6Male, *n*67BMI, kg/m^2^26.0 ± 4.6Histology, *n*Small cell lung cancer23Non-small cell lung cancer77- Adenocarcinoma45- Squamous cell carcinoma24- Other8Tumor stage (UICC), *n* I9 II13 III28 IV50Smoking history, *n* Current smoker48 Ex-smoker36 Never smoked16Comorbidities, *n* Hypertension56 Diabetes14 Coronary artery disease22 Chronic heart failure8 COPD29Values are mean ± standard deviation, or number of patients*BMI* body mass index, *COPD* chronic obstructive pulmonary disease, *UICC* Union for International Cancer ControlTable 2Sleep-disordered breathing analysis, daytime sleepiness and sleep qualityPatients (*n* = 100)ESS score6.3 ± 3.5PSQI score7.0 ± 3.2AHI, /h4.9 \[2.0, 10.4\]ODI, /h5.3 \[3.0, 10.1\]Mean SpO~2~, %91.3 ± 2.4Lowest SpO~2~, %78.2 ± 8.2Time with SpO~2~ \< 90%, min34.5 \[9.8, 78.0\]Heart rate, beats/min72.7 ± 11.8Respiration rate, breaths/min17.7 ± 4.9Snoring, /h66.6 \[22.7, 130.3\]Values are mean ± standard deviation, or median \[first quartile, third quartile\]*AHI* apnea-hypopnea index, *ESS* Epworth Sleepiness Scale, *ODI* oxygen desaturation index, *PSQI* Pittsburgh Sleep Quality Index, *SpO*~*2*~ oxygen saturation

SDB prevalence {#Sec9}
--------------

The overall prevalence of SDB (AHI \> 5/h) in the study population was 49% (95% CI 38.9--59.2%) and was higher in men (55%) versus women (36%). The median sleep time with oxygen saturation below 90% was 33.0 min for patients with SDB. Moderate to severe SDB was present in 17% (95% CI 10.2--25.8%), whereas mild SDB (AHI 5 to \< 15/h) was present in 32% (95% CI 23.0--42.1%) of the patients. There were several statistically significant differences between patients who had mild or moderate to severe SDB and those who did not, including AHI, and ODI (Table [3](#Tab3){ref-type="table"}). Patients with moderate to severe SDB showed mild daytime sleepiness (ESS score 8.24 ± 3.96), and were more sleepy than those without SDB or mild SDB (Table [3](#Tab3){ref-type="table"}). Sleep quality (PSQI), BMI, tumor histology and tumor stage were not significantly different between the three groups (Table [3](#Tab3){ref-type="table"}). The prevalence of distinct comorbidities was similar in the three groups. However, there was a trend towards a higher prevalence of COPD in patients without or with mild SDB compared to patients with moderate to severe SDB (29.4 and 37.5% vs. 11.8%) (Table [3](#Tab3){ref-type="table"}).Table 3Comparison of patients without (AHI \< 5/h), with mild (AHI 5--15/h)or moderate to severe (AHI \> 15/h) sleep-disordered breathingAHI \< 5/hAHI 5--15/hAHI \> 15/h*p*-valuen513217N/AAge, years66.31 ± 8.4869.16 ± 8.0671.35 ± 8.7750.0736Male, *n* (%)30 (58.8)24 (75.0)13 (76.5)0.2062BMI, kg/m^2^25.53 ± 4.4526,67 ± 4,9526.41 ± 4.140.5133AHI, /h2 \[1, 3\]7.7 \[5.4, 10.4\]25.2 \[18, 45.5\]\< 0.0001ODI, /h3.1 \[1.5, 5.1\]8.5 \[4.2, 13.4\]20.6 \[9.6, 36.6\]\< 0.0001Mean SpO~2~, %91.47 ± 2.5691.09 ± 2.3691.35 ± 2.140.7900Time with SpO~2~ \< 90%, min36 \[8, 84\]25.5 \[8.3, 92.3\]41 \[10.5,63\]0.9999ESS score5.74 ± 3.536.22 ± 2.728.24 ± 3.960.0343PSQI score6.49 ± 2.697.97 ± 3.976.71 ± 2.620.1137Snoring, /h69 \[19.6, 148\]61.2 \[26.8, 156.4\]69 \[30.5,89.7\]0.9343Histology, *n* (%) SCLC14 (27.5)4 (12.5)5 (29.4)0.2280 NSCLC37 (72.5)28 (87.5)12 (70.6)- Adenocarcinoma22 (43.1)18 (56.3)5 (29.4)0.7034- Squamous cell carcinoma12 (23.5)7 (21.9)5 (29.4)- Other3 (5.9)3 (9.4)2 (11.8)Tumor stage (UICC), *n* (%) I3 (5.9)4 (12.5)2 (11.8)0.1556 II5 (9.8)3 (9.4)5 (29.4) III19 (37.3)7 (21.9)2 (11.8) IV24 (47.1)18 (56.3)8 (47.1)Smoking history, *n* (%) Current smoker27 (52.9)14 (43.8)7 (41.2)0.8782 Ex-smoker16 (31.4)13 (40.6)7 (41.2) Never smoked8 (15.7)5 (15.6)3 (17.6)Comorbidities, *n* (%) Hypertension26 (50.1)21 (65.6)9 (52.9)0.4088 Diabetes4 (7.8)6 (18.8)4 (23.5)0.1749 Coronary artery disease9 (17.6)7 (21.9)6 (35.3)0.3144 Chronic heart failure4 (7.8)3 (9.4)1 (5.9)0.9105 COPD15 (29.4)12 (37.5)2 (11.8)0.1670Pulmonary function FEV1 (% predicted)64.69 ± 17.8867.51 ± 18.6577.09 ± 20.020.0926 PaO~2~ (mmHg)67.62 ± 12.4466.69 ± 9.0169.34 ± 17.690.9264Values are mean ± standard deviation, median \[first quartile, third quartile\], or number of patients (%)*AHI* apnea-hypopnea index, *BMI* body mass index, *COPD* chronic obstructive pulmonary disease, *ESS* Epworth Sleepiness Scale, *FEV1* Forced Expiratory Volume in 1 s, *NSCLC* non-small cell lung cancer, *ODI* oxygen desaturation index, *PaO*~*2*~ capillary partial pressure of oxygen, *PSQI* Pittsburgh Sleep Quality Index, *SpO*~*2*~ oxygen saturation, *SCLC* small cell lung cancer, *UICC* Union for International Cancer Control

Comparing AHI across different tumor stages showed a lower AHI in stage III compared with earlier stages (median 5.1/h, 5.0/h, 2.3/h, and 5.1/h for stages I, II, III, and IV, respectively; *p* = 0.04) (Fig. [1](#Fig1){ref-type="fig"}). There were no significant differences in AHI by histologic tumor type (Fig. [2](#Fig2){ref-type="fig"}). Median sleep time spent with oxygen saturation below 90% was 14, 24, 45, and 33 min in stages I, II, III, and IV, respectively (Fig. [3a](#Fig3){ref-type="fig"}), and time with oxygen saturation below 90% also did not differ between different histological tumor types (Fig. [3b](#Fig3){ref-type="fig"}).Fig. 1Relationship between the apnea-hypopnea index (AHI) and UICC tumor stageFig. 2Relationship between the apnea-hypopnea index (AHI) and different subtypes of lung cancerFig. 3Relationship between sleep time with oxygen saturation \< 90% (*T* \< 90%) and different tumor stages (**a**) or tumor histology (**b**)

Clinical predictors for SDB {#Sec10}
---------------------------

The best fitting regression model for the prediction of SDB included age, sex, BMI, and UICC categories II, III, and IV, with estimated regression coefficients of 0.03 (95% CI --0.01, 0.06), 0.57 (− 0.03, 1.17), 0.02 (− 0.05, 0.08), 0.14 (− 1.05,1.34), − 1.03 (− 2.09, 0.04), and − 0.29 (− 1.30, 0.73), respectively. The adjusted r-squared was 0.11, indicating that the model had weak predictive value.

Discussion {#Sec11}
==========

This study reports the prevalence of SDB in patients with newly-diagnosed lung cancer for the first time and showed that nearly half of all patients had any SDB (AHI \> 5/h) and that the prevalence of moderate to severe SDB in this population was 17%.

The reported prevalence of SDB is dependent on the AHI cutoff value used. \[[@CR13], [@CR14]\] The 17% prevalence rate for moderate to severe SDB in our cohort with newly-diagnosed lung cancer lies within the estimated prevalence range in the general population (5 to 20%). \[[@CR1], [@CR2]\] When an AHI cutoff value of 5/h was used, the estimated prevalence of SDB in patients with newly-diagnosed lung cancer rose markedly to 49%. Of note the average BMI was in the normal range and not significantly different between the groups. Hence one could speculate that the prevalence of SDB is even increased in lung cancer patients. However, as we do not have a control group with similar anthropometric characteristics not suffering from lung cancer this cannot be deducted from the results of the current study.

The exact prevalence of SDB in patients with lung cancer may be less important than the fact that our study shows that a high proportion of patients with newly-diagnosed lung cancer have undiagnosed SDB. This might be particularly relevant given that previous studies have shown that SDB is associated with both increased cancer incidence and increased cancer mortality. \[[@CR4]--[@CR7]\] If this is also the case for patients with lung cancer, screening for SDB in these patients is likely to be clinically important.

Both increased cancer incidence and increased cancer mortality have been shown to be dependent on the severity of hypoxemia occurring during SDB,^4,6^ and animal data demonstrated an association between intermittent hypoxia and tumor growth and progression. \[[@CR8]\] The mean ODI in the present study was 9 ± 12/h overall and 25 ± 20/h in patients with moderate to severe SDB. Although intermittent hypoxia was present in our cohort we did not find any correlation between the severity of SDB and cancer type or tumor stage. Furthermore, sleep time with oxygen saturation below 90% was not correlated with cancer type or tumor stage. However, this was not the goal of the current study and the trial was not powered for these analyses. Nevertheless, our results might stimulate research to assess clinical outcomes in lung cancer patients with underlying SDB. Continuous positive airway pressure is the standard of care for patients with obstructive sleep apnea, improving both the AHI and ODI. \[[@CR16]\] Therefore, studies investigating the impact of treating intermittent hypoxia in patients with lung cancer on the clinical course of the disease would be of high clinical interest.

Sleep apnea is associated with impaired health-related quality of life due to symptoms such as reduced sleep quality, daytime sleepiness, and fatigue. \[[@CR16]\] Chronic fatigue is a common problem in patients with lung cancer, \[[@CR17]\] which might be aggravated in the presence of SDB or, in some instances, may even be caused by SDB. Although sleep quality measured using the PSQI was not different in patients with and without SDB, daytime sleepiness based on the ESS score, was significantly higher in newly-diagnosed lung cancer patients who also had SDB. Therefore, treating SDB in patients with lung cancer might have the potential to improve SDB symptoms and thus also health-related quality of life. However, this remains speculative and should be evaluated in a prospective clinical trial.

In our cohort of patients with newly-diagnosed lung cancer, age, BMI, sex, and tumor stage did not predict SDB, but this may be due to a lack of statistical power for the analyses.

Our study has several limitations which have to be addressed: Firstly, the device used to screen for SDB has limited diagnostic abilities, e. g. it does not allow to distinguish obstructive from central sleep apnea. Secondly, the proportion of screening failures was high, and we did not collect data about the prevalence of SDB in a matched control group without lung cancer. Thirdly, SDB was assessed both at home and in hospital which might have yielded different results.

Conclusions {#Sec12}
===========

In conclusion, the rate of moderate to severe SDB in patients with newly-diagnosed lung cancer was 17% and nearly half of all patients had any SDB. Moderate to severe SDB in this cohort was associated with intermittent hypoxia and increased daytime sleepiness. Since previous studies have linked pathophysiological features of SDB, such as intermittent hypoxia, with tumor growth and progression, further research is warranted to determine whether SDB influences the outcome of patients with lung cancer and whether treatment of SDB can improve health-related quality of life, slow disease progression, or even increase survival in lung cancer patients.
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:   Oxygen desaturation index

SDB

:   Sleep disordered breathing
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